[1] Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab, 2004, 89(1):272-280.
[2] Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma:a comprehensive review. Endocr Relat Cancer, 2005, 12(1):49-64.
[3] Jarzab B, Handidewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma:a single-centre study of 54 patients. Eur J Nucl Mad Mol Imaging, 2003, 30(8):1077-1086.
[4] Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2000, 85(10):3640-3645.
[5] Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest, 2002, 25(1):44-52.
[6] de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131Ⅰ activities given after recom-binant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med, 2004, 45(9):1549-1554.
[7] Gruning T, Tiepolt C, Zophel K, et al. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?. Eur J Endocrinol, 2003, 148(4):395-402.
[8] Zarnegar R, Bmnaud L, Kanauchi H, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A, a histone deacetylase inhibitor.Surgery, 2002, 132(6):984-990.
[9] Pancini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131Ⅰ:a comparison in thyroid cancer pa-tients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab, 2002, 87(9):4063-4068.
[10] Bobbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as preparation for radioiodine thyroid remnant ablation. J Nucl Med, 2002, 43(11):1482-1488.
[11] Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer, effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metsb, 2003, 88(9):4110-4115.
[12] Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of meta static differentiated thyroid cancer in patients on L-thyroxine,using recombinant human TSK Eur J Endocrinol, 2001, 144(1):5-11.
[13] Pellegriti G, Scollo C, Giuffrida D, et al. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid, 2001, 11(11):1025-1030.
[14] Kovatcheva RD, Hadjieva TD, Kirilov GG, et al. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nucl Med Rev Cent East Eur, 2004, 7(1):13-19.
[15] Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab, 1999, 84(11):3877-3885.
[16] Mazzaferri EL, Massoll N. Management of papillary and follicular(differentiated) thyroid cancer:, new paradigms using recombinant human thyrotropin. Endocr Relat Cancer, 2002, 9(4):227-247.
[17] Schmutzler C, Hoang-Vu C, Ruger B, et al. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol, 2004, 150(4):547-556.
[18] Schmutzler C, Kohrle J. Retinoic acid redifferentialion therapy for thyroid cancer. Thyroid, 2000, 10(5):393-406.
[19] Dadachova E, Carrasco N. The Na/I symporter (NLS):imaging and therapeutic applications. Semin Nucl Med, 2004, 34(1):23-31.
[20] Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab, 2000, 85(8):2889-2896.
[21] Hoang-Vu C, Bull K, Schwarz I, et al. Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab, 1999, 84(3):1104-1109.
[22] Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferenfiation therapy of advanced thyroid cancer:final results of a pilot study. Eur J Nucl Mad Mol Imaging, 2002, 29(6):775-782.
[23] Short SC, Suovuori A, Cook G, et al. A phase Ⅱ study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol, 2004, 16(8):569-574.
[24] Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab, 2001, 86(7):3430-3435.
[25] Kitazono M, Bates S, Fok P, et al. The histone deacetylese inhibitor FR901228(desipeptide) restores expression and function of pseudo-null p53. Cancer Bid Ther, 2002, 1(6):665-668.
[26] Imanishi R, Ohtsuru A, Iwamatsu M, et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab, 2002, 87(10):4821-4824.